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From an evolutionary perspective, the convergence of multiple, biochemically unrelated functions into a single protein constitutes a valuable strategy for organisms to economize genetic and metabolic resources ([@bib116]). Nonetheless, there is a general tendency to attribute unique functions to specific proteins, often reflecting the earliest or most abundant literature on the topic. As an example, while caspase 3 (CASP3) is globally recognized as a key effector in apoptosis ([@bib27], [@bib112]), its non-apoptotic role in the differentiation of multiple cell types ([@bib80]) is largely underappreciated. The same issue applies to hundreds other proteins that have been characterized mostly, if not only, in the context of a single cellular process, including multiple components of the molecular machinery for macroautophagy.

Macroautophagy is an evolutionarily conserved stress-responsive process that disposes of superfluous or potentially dangerous cytosolic entities (e.g., damaged mitochondria, invading pathogens) upon sequestration within double-membraned vesicles (autophagosomes) and delivery to lysosomes for degradation ([@bib24], [@bib58]) ([Figures 1](#fig1){ref-type="fig"}A and 1B). Two other forms of autophagy have been described: (1) microautophagy, which involves the delivery of autophagy substrates to lysosomes upon invagination of the lysosomal membrane, and (2) chaperone-medicated autophagy (CMA), which relies on a specific splicing isoform of lysosomal-associated membrane protein 2 (LAMP2) as a translocase for KFERQ-containing cytosolic proteins into the lysosomal lumen ([@bib49], [@bib60]). The molecular apparatus that underlies these multiple variants of autophagy has been characterized with increasing precision ([@bib16]) ([Box 1](#tbox1){ref-type="boxed-text"} ). The crosstalk between *bona fide* autophagic responses and multiple other cellular processes has also been intensively investigated. Thus, it has become clear that autophagy occupies a central position in the biology of most eukaryotes, interfacing with the regulation of core metabolism ([@bib35], [@bib114]), damage control ([@bib21], [@bib50], [@bib71]), and cell death ([@bib32], [@bib126], [@bib128]). Until recently, however, relatively little attention has been given to the possibility that components of the autophagy apparatus could mediate non-autophagic functions ([@bib58]).Figure 1Degradative Autophagic Responses, Autophagy Blockade, and Non-autophagic Functions of Autophagy Machinery(A) In physiological conditions, autophagosomes form (1) and successfully fuse with lysosomes (2) at baseline rates, underling the ability of autophagy to support normal cellular functions.(B) In the presence of an autophagic stimulus such as nutrient deprivation, the rate of autophagosome formation (3), autophagosome-lysosome fusion, and lysosomal degradation increases (4), resulting in accelerated degradation of autophagic substrates.(C) Autophagosomes also accumulate in the absence of an upstream autophagic stimulus (5) when lysosomal functions are inhibited (6), such as in the presence of lysosomotropic agents.(D) Finally, the autophagosome compartment expands, driven by an upstream stimulus (7), when autophagosomal content is destined to secretion, either upon (8) or independent of (9) fusion with lysosomes in the absence of lysosomal degradation. Thus, widely employed assays only based on the maturation of LC3 not only are unable to determine whether an expansion of the autophagosomal compartment compared to baseline (A) reflects upstream autophagy activation coupled to efficient lysosomal degradation (B) or downstream inhibition of autophagosome-lysosome fusion or lysosomal acidification (C), but also they cannot identify situations in which activation of upstream autophagy-relevant signaling modules mediate non-autophagic effects (D).Box 1Principles of Autophagy Regulation in MammalsCanonical autophagic responses, which are best exemplified by starvation-driven autophagy, can be schematically subdivided into five phases: (1) initiation, (2) phagophore nucleation, (3) phagophore expansion and substrate selection, (4) autophagosome-lysosome fusion, and (5) lysosomal substrate degradation ([@bib25]). During initiation, the bioenergetic stress imposed by decreased nutrient availability manifests with increasing AMP levels, resulting in the activation of AMPK and consequent (1) inactivating phosphorylation of mechanistic target of rapamycin (MTOR) complex 1 (MTORC1) and (2) direct activating phosphorylation or indirect activating dephosphorylation (as a consequence of MTORC1 inhibition) of multiple proteins involved in initiation (e.g., ATG13, ULK1) and nucleation (e.g., ATG14, AMBRA1, UVRAG, BECN1). In this setting, ULK1 operates as part of a multiprotein complex containing ATG13, ATG101, and FIP200. ULK1-, AMPK-, and MTORC1-related phosphorylation/dephosphorylation events trigger phagophore nucleation (mostly at the ER) upon PI3P production by a supramolecular complex with class III PI3K activity consisting of VPS34 (the catalytic subunit), VPS15, BECN1, AMBRA1, and/or UVRAG, coupled to recruitment of ATG9-containing vesicles. The activity of this complex is under tonic inhibition by BCL2, reflecting the ability of BCL2 to engage in physical inhibitory interactions with BECN1. Phagophore elongation involves two ubiquitin-like conjugation systems. On one hand, ATG7 and ATG10 operate sequentially to catalyze the formation of ATG12-ATG5:ATG16L1 complexes. On the other hand, ATG4, ATG7, and ATG3 cooperate to cleave the precursors of LC3-like proteins into their mature forms, followed by conjugation to phosphatidylethanolamine (PE) and recruitment to autophagosomes forming with the support of WIPI proteins. LC3 and LC3 homologues enable autophagosomes with the ability to bind autophagic substrates and/or proteins that mediate cargo selectivity (including p62). Indeed, while autophagic responses to nutrient deprivation are relatively non-selective, multiple other variants of autophagy exhibit exquisite substrate specificity. On closure, autophagosomes fuse with lysosomes to generate autolysosomes, generally followed by luminal acidification and consequent activation of lysosomal hydrolases that mediate substrate degradation. This latter step, which appears to involve (at least to some extent) the conjugation systems responsible for elongation ([@bib123]), is critical to discriminate *bona fide* autophagic responses from autophagy-independent functions of the autophagic machinery ([@bib24]).P, inorganic phosphate.

Along with methodological issues linked to widely employed approaches to measure degradative macroautophagy (from here onward referred to as autophagy) ([@bib20]), such under-appreciation of biological complexity may have considerably confounded the interpretation of hundreds of experiments investigating the impact of autophagy on several physiological and pathological states ([Figures 1](#fig1){ref-type="fig"}C and 1D). In particular, this may have led investigators to misattribute phenotypic or functional effects caused by the pharmacological or genetic perturbation of single autophagy-regulatory factors to autophagy as a process ([@bib25]). Accumulating evidence suggests indeed that most, if not all, components of the molecular apparatus for autophagy mediate one or multiple effects that do not depend on lysosomal degradation of autophagy substrates ([Table 1](#tbl1){ref-type="table"} ). In particular, autophagy-relevant proteins mediate non-autophagic effects that impinge on cellular functions linked to membrane biology, such as (1) endocytosis, phagocytosis, and intracellular vesicular trafficking; (2) conventional and non-conventional secretion; and (3) cytokinesis, as well as on (at least apparently) membrane-unrelated functions, such as (1) inflammatory and immune responses, (2) cell death, (3) genomic stability, and (4) cell proliferation ([Table 2](#tbl2){ref-type="table"} ). Moreover, several pathogens acquired the ability to hijack non-autophagic functions of the autophagy machinery for their own benefit, suggesting that such functions may have appeared early in the course of host-pathogen co-evolution ([@bib9], [@bib19]).Table 1Non-autophagic Functions of Core Components of the Autophagy ApparatusProteinAutophagic RoleNon-autophagic Role(s)ReferencesAMBRA1NucleationADCD[@bib117]ATG12ElongationADCD; Exosome secretion; LAP; Pathogen control[@bib34], [@bib43], [@bib65], [@bib69], [@bib70], [@bib79], [@bib101], [@bib104]ATG13InitiationADCD; Pathogen control[@bib29], [@bib73]ATG14NucleationADCD[@bib65]ATG16L1ElongationExosome secretion; LAP; Phagocytosis; Pathogen control; PRR signaling[@bib33], [@bib43], [@bib69], [@bib70], [@bib79], [@bib104], [@bib106], [@bib113], [@bib131]ATG3ElongationCell proliferation; Exosome secretion; LAP[@bib69], [@bib70], [@bib79], [@bib83], [@bib104]ATG4BElongationGranule exocytosis; LAP[@bib15], [@bib69], [@bib70], [@bib104]ATG5ElongationADCD; Cell proliferation; Exosome secretion; Granule exocytosis; Immunological memory; LAP; Non-canonical protein secretion; Pathogen control; Vision cycle[@bib15], [@bib17], [@bib30], [@bib33], [@bib43], [@bib51], [@bib52], [@bib53], [@bib65], [@bib69], [@bib70], [@bib83], [@bib86], [@bib88], [@bib90], [@bib104], [@bib132], [@bib140], [@bib141]ATG7ElongationADCD; Cell proliferation; Cytokine secretion; Exosome secretion; Granule exocytosis; Immunological memory; LAP; Pathogen control; PRR signaling[@bib15], [@bib30], [@bib41], [@bib43], [@bib57], [@bib65], [@bib69], [@bib70], [@bib79], [@bib86], [@bib88], [@bib90], [@bib104], [@bib106], [@bib108], [@bib132]ATG9InitiationADCD; Phagocytosis[@bib44], [@bib124], [@bib131]BECN1NucleationADCD; LAP; Centrosome functions; Cytokinesis; Endocytosis; Vision cycle[@bib18], [@bib51], [@bib65], [@bib69], [@bib70], [@bib74], [@bib99], [@bib85], [@bib104], [@bib107], [@bib121], [@bib138]BIF-1NucleationCytokinesis; Endocytosis[@bib121]FIP200InitiationPathogen control[@bib73]IRGMUnclearADCD[@bib111]LC3Cargo selectionBacterial replication[a](#tblfn1){ref-type="table-fn"}; Cytokine secretion; Granule exocytosis; LAP; Pathogen control; Vision cycle; Viral replication; Viral release[@bib3], [@bib2], [@bib15], [@bib51], [@bib69], [@bib70], [@bib86], [@bib104], [@bib106], [@bib109], [@bib129]NDP52Cargo selectionPathogen control[@bib106]p62Cargo selectionADCD; Pathogen control[@bib30], [@bib106]RAB7AFusionEndocytosis; Exosome secretion; Granule exocytosis; Non-canonical protein secretion[@bib15], [@bib17], [@bib45], [@bib63], [@bib89]RUBCNNucleationLAP; Vision cycle[@bib69], [@bib70], [@bib78], [@bib104]ULK1InitiationCytokine secretion; ER-to-GA anterograde transport[@bib46], [@bib62], [@bib127]ULK2InitiationER-to-GA anterograde transport[@bib46], [@bib127]UVRAGInitiationCell proliferation; Centrosome functions; Cytokinesis; DNA repair; Endocytosis; GA-to-ER retrograde transport; LAP; Melanogenesis[@bib1], [@bib36], [@bib56], [@bib63], [@bib69], [@bib70], [@bib74], [@bib89], [@bib104], [@bib121], [@bib134], [@bib135], [@bib142]VPS15NucleationCytokinesis; Endocytosis[@bib121]VPS34NucleationADCD; Cytokinesis; Endocytosis; GA-to-ER retrograde transport; LAP[@bib30], [@bib36], [@bib65], [@bib69], [@bib70], [@bib74], [@bib104], [@bib121], [@bib138][^1][^2]Table 2Major cellular functions involving components of the autophagy machineryFunctionsProteinAutophagic RoleReferences**Related to membrane biology**Cytokine secretionATG7Elongation[@bib41], [@bib62]ULK1InitiationCytokinesisBECN1Nucleation[@bib121], [@bib138]BIF-1NucleationUVRAGInitiationVPS15NucleationVPS34NucleationULK1InitiationEndocytosisBECN1Nucleation[@bib56], [@bib63], [@bib74], [@bib89], [@bib99], [@bib107], [@bib121]BIF-1NucleationRAB7AFusionUVRAGInitiationVPS15NucleationVPS34NucleationER-to-GA anterograde transportULK1Initiation[@bib46], [@bib127]ULK2InitiationExosome secretionATG12Elongation[@bib33], [@bib45], [@bib79], [@bib108]ATG16L1ElongationATG3ElongationATG5ElongationATG7ElongationRAB7AFusionGA-to-ER retrograde transportVPS34Nucleation[@bib36]UVRAGInitiationGranule exocytosisATG4BElongation[@bib15], [@bib86]ATG5ElongationATG7ElongationLC3Cargo selectionRAB7AFusionLAPATG12Elongation[@bib69], [@bib70], [@bib104]ATG16L1ElongationATG3ElongationATG4BElongationATG5ElongationATG7ElongationBECN1NucleationLC3Cargo selectionRUBCNNucleationUVRAGInitiationVPS34NucleationMelanogenesisUVRAGInitiation[@bib135]Non-canonical protein secretionATG5Elongation[@bib17], [@bib53], [@bib140]RAB7AFusionPathogen control[a](#tblfn2){ref-type="table-fn"}ATG12Elongation[@bib43], [@bib52], [@bib73], [@bib106], [@bib141]ATG13InitiationATG16L1ElongationATG5ElongationATG7ElongationFIP200InitiationLC3Cargo selectionNDP52Cargo selectionp62Cargo selectionPathogen replication[b](#tblfn3){ref-type="table-fn"} and releaseLC3Cargo selection[@bib2], [@bib3], [@bib109], [@bib129]PhagocytosisATG16L1Elongation[@bib124], [@bib131]ATG9InitiationVision cycleATG5Elongation[@bib78], [@bib51]**Others**ADCDAMBRA1Nucleation[@bib18], [@bib29], [@bib30], [@bib34], [@bib44], [@bib57], [@bib101], [@bib111], [@bib117]ATG12ElongationATG13InitiationATG14NucleationATG5ElongationATG7ElongationATG9InitiationBECN1NucleationIRGMUnclearp62Cargo selectionVPS34NucleationCell proliferationATG3Elongation[@bib1], [@bib83], [@bib88]ATG5ElongationATG7ElongationUVRAGInitiationCentrosome functionsBECN1Nucleation[@bib85]DNA repairUVRAGInitiation[@bib134], [@bib142]Immunological memoryATG5Elongation[@bib90], [@bib132]ATG7ElongationPRR signalingATG7Elongation[@bib41], [@bib113]ATG16L1ElongationBECN1NucleationLC3Cargo selectionRUBCNNucleation[^3][^4][^5]

Here, we discuss emerging data on non-autophagic functions of components of the molecular apparatus for autophagy.

Endocytosis and Phagocytosis {#sec1.2}
----------------------------

Autophagy relies on the formation, maturation, and subcellular relocalization of autophagosomes, ultimately resulting in their fusion with lysosomes ([@bib24]). Not surprisingly, several components of the molecular machinery for autophagy regulate vesicular trafficking, including endocytosis and phagocytosis, often as signaling modules ([Figure 2](#fig2){ref-type="fig"} ).Figure 2Molecular Interface between Autophagy and Membrane BiologyMultiple components of the molecular machinery for autophagy mediate non-autophagic functions linked to the rearrangement and trafficking of intracellular membranes independently of *bona fide* autophagic responses. In this setting, different supramolecular entities can be assembled around components of the class III phosphatidylinositol 3-kinase complex that drives autophagy (A) to differentially regulate specific non-autophagic functions, including LC3-associated phagocytosis (C), endocytosis (C), melanogenesis (D), cytokinesis (E), and GA-to-ER transport (F).ER, endoplasmic reticulum; GA, Golgi apparatus; PI3P, phosphatidylinositol 3-phosphate.

Independently of their pro-autophagic functions, phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3, best known as VPS34), phosphoinositide-3-kinase regulatory subunit 4 (PI3KR4, best known as VPS15), and beclin 1 (BECN1) promote endocytosis and endosome maturation. UV radiation resistance-associated (UVRAG), a pro-autophagic BECN1 activator, also favors endocytosis through interactions with the class C vacuolar protein-sorting tethering complex and consequent increase in RAB7A activity ([@bib63], [@bib89]). Initially, such an effect, which involves accelerated endosomal maturation, was believed to be unrelated to BECN1 and the VPS34 complex ([@bib63]). However, at least in some cell types, VPS34 and VPS34 interactors involved in the control of growing membranes, including BECN1, VPS15, and SH3 domain containing GRB2 like, endophilin B1 (SH3GLB1, best known as BIF-1), have been implicated in this process, with no apparent roles for other VPS34 regulators such as ATG14 and RUN and cysteine-rich domain containing beclin 1 interacting protein (RUBCN) ([@bib74], [@bib121]). Thus, while mice with a cerebellum-specific knockout of *Atg7* exhibit a neurodegenerative disorder that develops over multiple months, the deletion of *Becn1* from the same cellular compartment imposes rapid neurodegeneration ([@bib74]). Most likely, this difference reflects the endocytic defect imposed by the loss of BECN1, leading to alterations in growth factor receptor signaling ([@bib74]). Reinforcing this notion, downregulation of BECN1 (which is a common event in human tumors) ([@bib120], [@bib139]) has been associated with increased AKT serine/threonine kinase 1 (AKT1) signaling in breast cancer cells ([@bib99]). Such an observation could be ascribed to defective endosomal maturation in BECN1-incompetent cells, resulting in increased residency of growth factor receptors at phosphatidylinositol 3-phosphate (PI3P)-negative signaling-competent endosomal compartments ([@bib99]). The function of BECN1 and UVRAG in endocytosis appears to be evolutionarily conserved ([@bib56], [@bib107]).

PI3P-bound UVRAG localizes to the endoplasmic reticulum (ER), where it interacts with RAD50 interactor 1 (RINT1) to constitute a tethering platform for vesicles coming in from the Golgi apparatus (GA) in the context of retrograde transport ([@bib36]). Both downregulation of UVRAG and PI3P depletion cause defects in Golgi-to-ER retrograde transport that are not linked to the autophagic functions of UVRAG ([@bib36]). However, autophagy induction by starvation and rapamycin results in the redistribution of UVRAG from RING1-containing complexes to BECN1-, VPS34- and BIF-1-containing complexes and consequent ATG9 recruitment at sites of autophagosome production ([@bib36]). This scenario exemplifies the mutual regulation of two biological functions based on the limited availability of a common molecular player. Interestingly, *Uvrag* ^*−/−*^ mouse melanoma cells display significant whitening as compared to their wild-type counterparts, a phenotype that cannot be recapitulated by ATG5, ATG16L1 or BECN1 depletion, or pharmacological VPS34 inhibition ([@bib135]). In this context, loss of UVRAG destabilizes a supramolecular entity involved in endosome-to-melanosome fusion commonly known as BLOC-1 complex, an effect that is not sensitive to lysosomal inhibition ([@bib135]). At least in some cells, a BECN1- and UVRAG-containing, ATG14-independent PI3K complex has also been suggested to participate in the control of cytokinesis, the final stage of mitosis whereby daughter cells separate once their nuclei have divided ([@bib121], [@bib138]). These latter observations reinforce the notion that multiple modules of the autophagy apparatus regulate the rearrangement of cellular membranes.

A specific form of phagocytosis engaged by several pathogens and dead cell corpses, which is known as LC3-associated phagocytosis (LAP), depends on several proteins involved in *bona fide* autophagic responses ([@bib69], [@bib70], [@bib104]). These include not only UVRAG, BECN1, and VPS34, which promote autophagy as a part of a single supramolecular entity, but also ATG3, ATG4, ATG5, ATG7, ATG12, ATG16L1, and multiple members of the microtubule-associated protein 1 light chain 3 (MAP1LC3, best known as LC3) family, which are all involved in the two major conjugation systems required for canonical autophagy ([Box 1](#tbox1){ref-type="boxed-text"}) ([@bib69], [@bib70], [@bib104]). Importantly, LAP differs from *bona fide* autophagy in that (1) it targets to lysosomal degradation extracellular entities that never acquire a cytosolic localization and (2) it relies on single-membraned vesicles ([@bib24]). Moreover, LAP occurs independently of unc-51 like autophagy-activating kinase 1 (ULK1), autophagy and beclin 1 regulator 1 (AMBRA1), ATG14, and RB1-inducible coiled-coil 1 (RB1CC1, best known as FIP200), which are all involved in autophagy, but relies on RUBCN, NAPDH oxidase 2, and the WD domain of ATG16L1, which are all dispensable for autophagy ([@bib22], [@bib69], [@bib70], [@bib93]). Thus, the deletion of *Becn1*, *Atg5*, or *Atg7* (but not *Rb1cc1*) from myeloid cells drives an autoimmune disorder similar to human systemic lupus erythematosus (SLE), which can be recapitulated by the whole-body knockout of *Rubcn* but not by that of *Ulk1* ([@bib70]). Similarly, the myeloid cell-specific deletion of *Becn1*, *Pik3c3*, *Atg5*, *Atg7*, or *Atg16l1* (but not *Rb1cc1* or *Atg14*) as well as the whole-body knockout of *Rbcn* or *Cybb* (coding for a subunit of NADPH oxidase 2), but not *Ulk1*, promotes anti-tumor T cell immunity as a consequence of improved inflammatory responses to dead cell corpses ([@bib12]). In the retinal epithelium, BECN1, ATG5, RUBCN, and LC3 are required for the phagocytosis of photoreceptor outer segments (POS), which is fundamental for normal vision ([@bib51], [@bib78]). This process, however, occurs independently of ULK1, ATG13, and FIP200, which are all required for conventional autophagic responses ([@bib51]). Thus, at least some of the phenotypes originating from the depletion of the aforementioned proteins may stem from defects in LAP, not autophagy, especially in the context of pathogen control and disposal of cell corpses ([@bib38]). Interestingly, the orthologs of ATG9 and ATG16L1 also mediate autophagy-independent pro-phagocytic effects in *Dictyostelium discoideum*, a simple eukaryote that transitions from unicellular to multicellular life over the course of its vital cycle ([@bib124], [@bib131]). Along with the notion that autophagy is conserved in both unicellular eukaryotes and plants ([@bib125]), this observation suggests that both the autophagy-dependent and autophagy-independent functions of the autophagic machinery may have appeared early during evolution.

Conventional and Non-conventional Secretion {#sec1.3}
-------------------------------------------

Conventional protein secretion involves the anterograde transport of ER-derived vesicles to the GA, vesicle trafficking from the *cis* though the *trans* GA, and ultimately, fusion of vesicles released from the *trans* GA with the plasma membrane ([@bib7]). Although this process has been intensively investigated, only recently it has become clear that, at least in some cell types, components of the autophagic machinery are required for conventional protein secretion.

Mice with a brain-specific co-deletion of *Ulk1* and *Ulk2* are born at Mendelian ratios yet die rapidly after birth (40% in the first 24 h) owing to massive degeneration of pyramidal neurons in the CA1 region ([@bib46]). Mice with conditional *Ulk1/Ulk2* co-deletion in the brain surviving the first 24 h after birth resemble their *Atg5*- and *Atg7*-deficient counterparts as they display abnormal limb-clasping reflexes, but they do not develop cerebellar ataxia, suggesting that the neuronal phenotype caused by the lack of *Ulk1* and *Ulk2* may not result from an autophagic defect ([@bib46]). Indeed, *Ulk1* ^*−/−*^ *Ulk2* ^*−/−*^ neurons do not exhibit accumulation of autophagic substrates such as sequestosome 1 (SQSTM1, best known as p62) but manifest signs of the unfolded protein response ([@bib46], [@bib127]), an intracellular pathway of adaptation to accumulation of unfolded polypeptides in the ER lumen ([@bib28]). Consistently, both ULK1 and ULK2 can phosphorylate SEC16 homolog A, endoplasmic reticulum export factor (SEC16A) to drive the anterograde transport of ER-derived vesicles to the GA, and this pathway is insensitive to depletion of ATG13 (which is required for the pro-autophagic functions of ULKs), ATG14, and ATG7 ([@bib46]). Of note, neurodegeneration imposed by *Ulk1/Ulk2* co-deletion is also accompanied by defective axonal pathfinding affecting multiple areas of the forebrain, and similar alterations cannot be recapitulated by the brain-specific deletion of *Atg7* or *Rb1cc1* ([@bib127]). However, to what extent these defects in axonal projection reflect secretory alterations in post-synaptic cells as opposed to primary deficiencies in pre-synaptic cells remains to be clarified. In apparent contrast with the observations discussed here above, ULK1 is not required for the secretion of type I interferon (IFN) by plasmacytoid dendritic cells (pDCs) exposed to DNA-immunoglobulin complexes, whereas ATG7 is required ([@bib41]). In this setting, however, ATG7 does not promote anterograde ER-to-GA vesicle trafficking but enables pDCs to take up DNA-immunoglobulin complexes via LAP, followed by Toll-like receptor 9 (TLR9) signaling at acidified phagosomes ([@bib41]). Intriguingly, Atg1, the ortholog of mammalian ULK1 in *Drosophila melanogaster*, is also involved in JNK-driven secretion of mitogens that underlies apoptosis-induced compensatory proliferation, an effect that does not depend on multiple other components of the autophagy machinery in flies including Atg3, Atg6 (the BECN1 ortholog), Atg8 (the LC3 ortholog), and Vps34 ([@bib62]). Moreover, *Caenorhabditis elegans* lacking the worm homolog of mammalian *ULK1* (i.e., *unc-51*) display axonal defects that resemble those of *Ulk1* ^*−/−*^ *Ulk2* ^*−/−*^ neurons ([@bib39]). These observations suggest that the autophagy-independent functions of ULKs in conventional secretion evolved early during evolution.

In contrast to *Atg5* ^*−/−*^ and *Atg7* ^*−/−*^ neurons, colonic goblet cells lacking *Atg5*, *Atg7*, or *Map1lc3b* exhibit a secretory defect causing accumulation of intracellular mucin granules ([@bib86]). In this context, secretory alterations reflect the inability of goblet cells lacking *Atg5*, *Atg7*, or *Map1lc3b* to produce reactive oxygen species (ROS) in sufficient amounts to drive granule exocytosis, secondary to a defect in the formation of NADPH oxidase-competent subcellular compartments at the interface between autophagosomes and endosomes ([@bib86]). Along similar lines, cells unable to form non-conventional ATG3-ATG12 conjugates, which are formed by ATG7 but are not involved in *bona fide* autophagic responses, accumulate autophagosomes and late endosomes in baseline conditions, coupled to reduced exosomal output ([@bib79]). A similar phenotype results from the deletion of *Atg5* or *Atg16l1* (but not *Atg7* or *Atg14*) from mouse embryonic fibroblasts (MEFs) as well as from the deletion of *ATG5* from human breast cancer cells, where it limits exosome-driven metastatic dissemination ([@bib33]). However, in the former setting, ATG3-ATG12 appears to drive exosome secretion upon interaction with the exosomal protein programmed cell death 6 interacting protein (PDCD6IP, best known as ALIX) ([@bib79]), while in the latter scenario, ATG5 appears to disrupt endosomal acidification by disassociating the V~1~V~0~-ATPase, resulting in diversion of late endosomes toward secretion (rather than lysosomal degradation) ([@bib33]). In some cases, ATG7 seems to be required for optimal exosome release (potentially linked to its role in ATG3-ATG12 conjugation) ([@bib79], [@bib108]), while in other settings, exosome release operates normally in the absence of ATG7 ([@bib33], [@bib103]). Irrespective of such unknowns, these observations link multiple components of the autophagy machinery to exosome secretion via autophagy-independent mechanisms.

The hypothesis that autophagy-relevant proteins could be involved in the release of intracellular material into the microenvironment irrespective of lysosomal degradation has first been formulated in the setting of "non-canonical secretion," a form of secretion of cytosolic entities devoid of leader peptides for ER translocation ([@bib92]). One of the substrates of non-conventional secretion is mature interleukin 1 beta (IL1B, best known as IL-1β), which is produced in the cytosol of cells with pro-inflammatory activity (like macrophages) upon proteolytic maturation of the IL-1β precursor by the NLRP3 inflammasome ([@bib94]). Bone-marrow-derived macrophages treated with nigericin (an inflammasome activator) secrete increased amounts of IL-1β in conditions of nutrient deprivation (as compared with nigericin-treated macrophages maintained in control conditions), and IL-1β secretion can be quenched by *Atg5* deletion ([@bib17]). ATG5-dependent IL-1β secretion appears to rely on recognition of two KFERQ-like motifs by heat shock protein 90 alpha family class A member 1 (HSP90AA1), resulting in the relocalization of IL-1β between autophagosomal membranes, potentially explaining why IL-1β does not undergo degradation within autolysosomes in this context ([@bib140]). Another (hitherto untested) possibility is that ATG5 may prevent IL-1β degradation by subverting autolysosomal acidification, reminiscent of the non-autophagic pathway whereby ATG5 regulates exosome production ([@bib33]). It has been proposed that IL-1β release ultimately depends on the fusion between autophagosomes or autolysosomes and the plasma membrane ([@bib53]). However, this model cannot be easily reconciled with the fact that gasdermin D (GSDMD), a core component of the molecular mechanism for pyroptosis ([Box 2](#tbox2){ref-type="boxed-text"} ), is also required for IL-1β secretion by macrophages ([@bib40]). How components of the autophagy machinery interface with pyroptosis regulators to control the non-canonical release of IL-1β remains to be elucidated.Box 2Principles of Cell Death Regulation in MammalsMammalian cells are provided with a complex molecular machinery that mediates their demise, a process commonly referred as regulated cell death (RCD) ([@bib27]). RCD occurs in both fully physiological and pathological settings. In the former case, RCD is instrumental to organismal development and homeostasis, as it ensures organ morphogenesis and adult tissue turnover. In the latter case, RCD is a consequence of failing adaptation to stress. That said, stress-driven RCD can also be viewed as a mechanism for the maintenance of organismal homeostasis, as it underlies the removal of damaged, non-functional, and potentially oncogenic cells ([@bib28]). The molecular mechanisms whereby mammalian cells undergo RCD in physiological and pathological scenarios exhibit considerable overlap. Extrinsic apoptosis is a form of RCD initiated by plasma membrane receptors through activation of CASP8, and precipitated by CASP3 or other executioner caspases, like CASP6 or CASP7. Intrinsic apoptosis also relies on CASP3, CASP6, or CASP7, but it is initiated by perturbations of intracellular homeostasis culminating with activation of pro-apoptotic BH3-only proteins and BAX- or BAK1-dependent mitochondrial outer membrane permeabilization (MOMP). Mitochondrial permeability transition (MPT)-driven regulated necrosis (RN) is initiated by the opening of a mitochondrial supramolecular entity known as permeability transition pore complex (PTPC) in response to oxidative stress or cytosolic Ca^2+^ overload and is precipitated by peptidylprolyl isomerase F (PPIF, best known as CYPD). Parthanatos is a form of regulated necrosis impinging on PARP1 hyperactivation, which entails a bioenergetic catastrophe coupled to the release of apoptosis-inducing factor mitochondria associated 1 (AIFM1; best known as AIF) from mitochondria and its translocation to the nucleus, where it mediates nucleolytic effects. Necroptosis is regulated by the RIPK3-dependent (and in some instances RIPK1-regulated) phosphorylation of MLKL, resulting in the formation of plasma-membrane-permeabilizing MLKL pores. Ferroptosis is triggered by oxidative perturbations, relies on lipid peroxidation, and is under tonic control by glutathione peroxidase 4 (GPX4). Pyroptosis is a form of RN impinging on the cleavage or gasdermin family members, such as gasdermin D (GSDMD) or GSDME, by inflammatory (i.e., CASP1, CASP4, CASP5, or CASP11) and apoptotic (i.e., CASP3) caspases often occurring in the context of IL-1β and IL-18 secretion. Lysosome-dependent cell death (LDCD) is a form of RCD demarcated by primary lysosomal membrane permeabilization (LMP) and precipitated by cathepsins, such as cathepsin B (CTSB) and CTSD. Finally, autophagy-dependent cell death (ADCD) relies on one of multiple components of the autophagy machinery ([@bib27]). Of note, the etiological involvement of lysosomal degradation of autophagy substrates in ADCD has not been exhaustively verified, at least in mammalian settings. Thus, several variants of ADCD may actually constitute autophagy-independent pathways under the control of one or more components of the molecular apparatus for autophagy.Cell Death ModePrototypic TriggerMain Initiator(s)Main Executor(s)Endogenous Inhibitor(s)Defining Event(s)Main MorphologyADCDVariousVariousVariousUnclearDependence on autophagy proteinsVacuolatedExtrinsic apoptosisDeath receptor ligationCASP8 or CASP10CASP3, CASP6, and CASP7CFLAR and anti-apoptotic BCL2 proteinsCaspase activationApoptoticFerroptosisSystem xc inhibitionIronOxidative damage to macromoleculesGPX4Lipid peroxidationNecroticIntrinsic apoptosisIntracellular stressPro-apoptotic BCL2 proteinsCASP3, CASP6, and CASP7Anti-apoptotic BCL2 proteinsMOMP and caspase activationApoptoticLDCDLysosomotropic agentsUnclearCTSB and CTSDCSTB and CSTCLMPApoptotic or necroticMPT-driven RNOxidative stressPTPCCYPDUnclearMPTNecroticNecroptosisTNFR1 ligation under caspase inhibitionRIPK1 and RIPK3MLKLUnclearMLKL oligomerizationNecroticParthanatosDNA damagePARP1AIF and bioenergetic catastrophe driven by NAD+ depletionUnclearPARP1 hyperactivationNecroticPyroptosisInflammasome activationCASP1, CASP3, CASP4, or CASP5GSDMD or GSDMEUnclearGasdermin oligomerizationNecrotic[^6]

A similar release of lysosomal material that depends on several components of the molecular apparatus for autophagy (i.e., ATG5, ATG7, ATG4B, and LC3), but does not involve *bona fide* degradation of autophagy substrates, has been linked to osteoclastic bone resorption ([@bib15]). In both non-conventional protein secretion and exosome secretion, members of the RAB protein family mediate the fusions of autophagosomes or lysosomes with the plasma membrane ([@bib15], [@bib17], [@bib45]). Since RAB proteins are also involved in *bona fide* autophagic responses ([@bib24]), however, they cannot be employed to molecularly discriminate between autophagy-dependent and autophagy-independent pathways. Clarifying the precise signals whereby formed autophagosomes are routed to secretion (directly or upon fusion with non-acidifying lysosomes) instead of delivering their content to disposal will be instrumental for the development of pharmacological agents with various clinical applications.

Inflammation and Innate Immunity {#sec1.4}
--------------------------------

*Bona fide* autophagic responses mediate robust anti-inflammatory functions as they dispose of potential triggers of inflammation, including (but not limited to) cytosolic pathogens, micronuclei, and permeabilized mitochondria ([@bib59]). In addition, various components of the autophagy machinery regulate inflammatory responses and contribute to intracellular pathogen control via autophagy-independent pathways.

While both *Atg5* ^*−/−*^ MEFs and MEFs expressing an autophagy-incompetent variant of ATG16L1 (ATG16L1-ΔCCD) exhibit defective autophagic responses to starvation, the former produce increased amounts of cytokine C-X-C motif chemokine ligand 1 (CXCL1) upon infection with cytoplasm-invading bacteria (as compared to wild-type MEFs), whereas the latter display a sub-optimal pro-inflammatory response ([@bib113]). Knockdown of ATG16L1-ΔCCD restores the ability of autophagy-deficient MEFs to secrete CXCL1 in response to infection ([@bib113]), supporting a non-autophagic role of ATG16L1 in the regulation of inflammatory responses. Consistent with this, transient knockdown of ATG16L1, but not ATG5, exacerbated CXCL1 secretion by mouse intestinal epithelial cells challenged with *Shigella flexneri*, *Listeria monocytogenes*, or *Salmonella enterica* serovar Typhimurium, an effect that could not be recapitulated with lysosomal inhibitors ([@bib113]). In this setting, both full-length ATG16L1 and ATG16L1-ΔCCD, but neither ATG5 nor ATG9, bind to nucleotide binding oligomerization domain containing 1 (NOD1) and NOD2, two intracellular sensors of bacterial invasion, to limit their ability to initiate receptor interacting serine/threonine kinase 2 (RIPK2) signaling in the presence of specific NOD1/NOD2 ligands or cytoplasmic bacteria detected by NOD1/NOD2, but not to TLR4 agonists or tumor necrosis factor (TNF) ([@bib113]). These findings delineate an anti-inflammatory function of ATG16L1 that occurs irrespective of autophagosome formation and lysosomal degradation.

Apparently at odds with its anti-inflammatory role in the course of bacterial infection, ATG16L1 supports the ability of IFN-γ to control infection in an autophagy-independent manner ([@bib43], [@bib106]). In particular, ATG16L1, ATG7, LC3, p62, and calcium binding and coiled-coil domain 2 (CALCOCO2, another protein involved in cargo selection, best known as NDP52) cooperate to encapsulate cytoplasmic *Toxoplasma gondii* (a eukaryotic parasite) in multi-membraned vesicles that efficiently blunt parasite replication but do not fuse with endosomes or lysosomes ([@bib106]). In this context, ATG5 appears to promote the recruitment of an IFN-γ-responsive GTPase to parasite-encapsulating vesicles, which is required for the optimal anti-infectious effects of IFN-γ ([@bib141]). It remains unclear whether the autophagy-independent functions of ATG16L1 and ATG5 in the control of *T. gondii* infection require the formation of the ATG12-ATG5-ATG16L1 complex. In partial support of this possibility, both ATG7, which catalyzes the ATG12-ATG5 conjugation, and the ATG12-ATG5-ATG16L1 complex are required for the control of murine norovirus infection by macrophages exposed to IFN-γ ([@bib43]), via a mechanism that does not rely on ATG4-dependent LC3 processing, autophagosome-lysosome fusion, or lysosomal degradation ([@bib43]). Conversely, expression of ATG5 (but not of ATG7, ATG12, and ATG16L1 nor of ULK1, ULK2, ATG3, ATG4, ATG14, and p62) in lysozyme 2 (LYZ2)^+^ cells (encompassing monocytes, macrophages, and neutrophils) is required for mice to control infection by *Mycobacterium tuberculosis* ([@bib52]). In this setting, ATG5 mediates autophagy-independent functions that prevent the development of severe lung inflammation driven by the release of multiple cytokines by polymorphic mononuclear cells (PMNs) ([@bib52]). Consistent with this, mice with a LYZ2-restricted deletion of *Atg5* (as well as mice where Atg5 is deleted only in PMNs) succumb prematurely to *M. tuberculosis* infection, and this can be rescued by PMN depletion ([@bib52]). The precise molecular mechanisms linking ATG5 to reduced inflammatory responses in PMNs challenged to *M. tuberculosis* remain obscure. However, because ATG7, ATG12, and ATG16L1 are not involved in this process ([@bib52]), the findings outlined above raise the intriguing possibility that *bona fide* autophagic responses may be detrimental in this setting as they could limit the availability of unbound ATG5. This hypothesis awaits experimental verification.

Components of the autophagy initiation complex ([Box 1](#tbox1){ref-type="boxed-text"}) have also been shown to mediate antiviral effects in an autophagy-independent manner. In particular, the replication of encephalomyocarditis virus (EMCV) and coxsackievirus B3 (CVB3) is enhanced in both *Atg13* ^*−/−*^ and *Rb1cc1* ^*−/−*^ MEFs (as compared with their wild-type counterparts), but a similar effect cannot be observed upon deletion of *Ulk1*, *Ulk2*, *Atg101*, or *Atg7* ([@bib73]). Consistently, transgene-enforced overexpression of ATG13 or FIP200 in HEK293 human kidney cancer cells considerably limits viral replication in the absence of ULK1 activation ([@bib73]). Of note, the lack of *Atg13* and *Rb1cc1* does not influence viral entry but rather boosts intracellular replication from 2- to 5-fold ([@bib73]). Whether such an effect depends on the ability of autophagy-related factors to regulate intracellular membranes, which is often hijacked by pathogens (see below), remains to be elucidated.

Cell Death {#sec1.5}
----------

In mammalian cells, *bona fide* autophagic responses most often mediate robust cytoprotective effects ([@bib6], [@bib102]). Indeed, while several instances of regulated cell death (RCD) ([Box 2](#tbox2){ref-type="boxed-text"}) rely on one or multiple autophagy-relevant proteins, hence constituting forms of autophagy-dependent cell death (ADCD) according to recent nomenclature guidelines ([@bib27]), in none of these cases does ADCD involve lysosomal degradation. Thus, at odds with ADCD in lower eukaryotes, which involves *bona fide* autophagic degradation ([@bib5], [@bib14]), ADCD in mammals stands out as an autophagy-independent pathway under the control of the autophagy machinery.

Neurons subjected to ischemic conditions and various human cancer cell lines exposed to nutrient deprivation or to a cell-permeant peptide that displaces BECN1 from inhibitory interactions with BCL2, apoptosis regulator (BCL2) ([Box 1](#tbox1){ref-type="boxed-text"}) undergo a variant of ADCD that relies on the plasma membrane Na^+^/K^+^ ATPase, which has been dubbed autosis ([@bib65]). Accordingly, neriifolin (a Na^+^/K^+^ ATPase inhibitor of the family of cardiac glycosides) mediates robust neuroprotective effects in rats experiencing cerebral hypoxia-ischemia ([@bib65]). Autosis occurs irrespective of BCL2-associated X, apoptosis regulator (BAX)- or BCL2 antagonist/killer 1 (BAK1)-dependent mitochondrial outer membrane permeabilization (MOMP) ([@bib65]), and hence, it does not constitute a form of apoptotic cell death. Rather, autosis relies on ATG5, ATG7, ATG12, ATG14, and BECN1 as well as the PI3K activity of VPS34 ([@bib65]). However, pharmacological inhibition of lysosomal functions fails to rescue human cervical carcinoma HeLa cells from autosis ([@bib65]), strongly suggesting that autosis occurs independently of *bona fide* autophagic responses.

ATG5, ATG7, and VPS34-dependent PI3P production are required for the necroptotic death ([Box 2](#tbox2){ref-type="boxed-text"}) of *Map3k7* ^*−/−*^ mouse prostate epithelial cells (MPECs), which lack a signal transducer in the pathway linking death receptor signaling to NF-κB activation, best known as TAK1, caused by exposure to TNF superfamily member 10 (TNFSF10, best known as TRAIL) ([@bib30]). Such necroptotic response is exacerbated, rather than blunted, by chemical inhibitors of lysosomal degradation ([@bib30]), pointing to a non-autophagic role for ATG5, ATG7, and VPS34 in this setting. Consistently, multiple components of the RIPK1- and RIPK3-containing complex that drives necroptosis colocalize with ATG5, ATG7, and p62 at autophagosomes in *Map3k7* ^*−/−*^ MPECs responding to TRAIL ([@bib30]). Moreover, depletion of p62 from *Map3k7* ^*−/−*^ MPECs switches TRAIL-driven necroptosis to apoptosis, which can be rescued with chemical caspase inhibitors ([@bib30]). Thus, in the absence of TAK1, autophagosomes favor necroptotic cell death by providing a physical platform for the activation of necroptosis, independent of autophagic substrate degradation.

Autophagy regulators also influence non-necroptotic forms of regulated necrosis. Developing *Atg9a* ^*−/−*^ embryos fail to manifest foci of cell death at the surface of multiple bones, resulting in impaired bone morphogenesis ([@bib44]). Such foci of dying cells fail to exhibit CASP3 activation and mixed lineage kinase domain like pseudokinase (MLKL) phosphorylation ([Box 2](#tbox2){ref-type="boxed-text"}) and can still be observed in *Casp9* ^*−/−*^ and *Ripk1* ^*−/−*^ embryos, implying that they do not originate from intrinsic apoptosis or necroptosis ([@bib44]). Moreover, *Atg5* ^*−/−*^ embryos exhibit normal bone morphogenesis at birth, implying that ATG9 regulates a programmed variant of necrosis irrespective of canonical autophagy ([@bib44]). Along similar lines, *Ulk1* ^*−/−*^ MEFs are protected from hydrogen-peroxide-driven RCD, but this phenotype cannot be recapitulated by the deletion of *Atg7* ([@bib47]). Rather, hydrogen-peroxide-driven RCD can be prevented by chemical inhibition or depletion of poly(ADP-ribose) polymerase 1 (PARP1) ([@bib47]), a mediator of parthanatos ([Box 2](#tbox2){ref-type="boxed-text"}). Moreover, ULK1 physically interacts with PARP1, especially in cells responding to oxidative stress, and such interaction stimulates the enzymatic functions of PARP1 to precipitate the bioenergetic catastrophe that underlies parthanatos ([@bib47]). Consistent with these observations, ATG13 silencing and consequent ULK1 destabilization limits the death of human osteosarcoma cells responding to the topoisomerase inhibitor camptothecin ([@bib29]). Although the involvement of PARP1 in the ability of ULK1 to support camptothecin toxicity has not been clarified, circumstantial evidence exists in support of such a link ([@bib13]).

Various autophagy regulators control apoptotic forms of RCD in an autophagy-independent manner. Immunity-related GTPase M (IRGM), the only human paralog of a large cluster of murine IFN-γ-regulated genes ([@bib4]), not only participates in the autophagic control of *M. tuberculosis* driven by IFN-γ ([@bib110]) but, upon infection, also translocates to mitochondria to initiate MOMP ([@bib111]). Importantly, RCD caused by IRGM occurs irrespective of BECN1 or ATG7 but can be rescued by co-deletion of *Bax* and *Bak1* ([@bib111]). Whether the ability of IRGM to trigger MOMP depends on a direct physical interaction with BAX and/or BAK1 versus the inactivation of anti-apoptotic Bcl-2 family members remains to be elucidated. This latter mechanism accounts for the pro-apoptotic effects of ATG12 ([@bib101]). Indeed, ATG12 contains a *bona fide* BH3 domain that enables ATG12 to interact with BCL2 and MCL1, BCL2 family apoptosis regulator (MCL1), ultimately resulting in BAX/BAK1-dependent RCD irrespective of ATG3, ATG4, and ATG5 ([@bib34], [@bib101]). Both BECN1 and AMBRA1 also contain a *bona fide* BH3 domain ([@bib84], [@bib117]). However, while interaction between BECN1 and BCL2 or BCL2-like 1 (BCL2L1, best known as BCL-X~L~) mainly regulates autophagic responses ([@bib67], [@bib87]), a cleavage product of AMBRA1 generated over the course of apoptosis appears to precipitate RCD upon BCL2 binding ([@bib117]). The reasons underlying such a discrepancy are unclear but may relate to the differential binding affinity of the AMBRA1 and BECN1 BH3 domains for Bcl-2 family members. BECN1 also competes with MCL1 for stabilization by ubiquitin specific peptidase 9 X-linked (USP9X) ([@bib18]). In this setting, increased levels of MCL1 limit BECN1 deubiquitination, hence favoring BECN1 proteasomal degradation. Such a simultaneous inhibition of autophagy and apoptosis has been documented in progressing melanomas ([@bib18]). Conversely, high levels of BECN1 favor the proteasomal degradation of MCL1, culminating with increased cellular susceptibility to apoptotic RCD ([@bib18]).

ATG7 can also regulate apoptotic RCD irrespective of degradative autophagy. Specifically, ATG7 can bind tumor protein p53 (TP53, best known as p53) to regulate p53 transcriptional activity ([@bib57]). Consistently, *Atg7* ^*−/−*^ MEFs as well as *Atg7* ^*−/−*^ MEFs reconstituted with an autophagy-incompetent variant of ATG7 (but not *Atg5* ^*−/−*^ and *Becn1* ^*−/−*^ MEFs) display defective p53-dependent cyclin dependent kinase inhibitor 1A (CDKN1A, best known as p21) expression and consequent cell-cycle arrest during starvation ([@bib57]). Interestingly, this phenotype is accompanied by accrued ROS generation and oxidative DNA damage, culminating in premature p53-driven, BAX/BAK1-dependent RCD ([@bib57]). Of note, p53 hyperactivation caused by the absence of ATG7 participates in the perinatal lethality of *Atg7* ^*−/−*^ mice ([@bib57]). These observations delineate an autophagy-independent mechanism whereby ATG7 regulates the activity of p53, both positively (as a consequence of physical interactions) and negatively (reflecting the establishment of accrued metabolic stress). The ultimate metabolic catastrophe promoted by the absence of ATG7 irrespective of *bona fide* autophagic responses may reflect the ability of p53 to support the maintenance of metabolic homeostasis at baseline ([@bib55]). This hypothesis awaits experimental validation.

Genomic Stability and Cell Proliferation {#sec1.6}
----------------------------------------

*Uvrag* ^*+/−*^ embryonic stem cells spontaneously accumulate DNA double-strand breaks and are more sensitive to DNA-damaging agents than their *Uvrag* ^*+/+*^ counterparts ([@bib142]). Similarly, human melanoma cells depleted of UVRAG display increased sensitivity to UV-driven DNA photolesions ([@bib134]). Moreover, UVRAG-deficient MEFs are prone to centrosome abnormalities and consequent mitotic defects that favor aneuploidy ([@bib142]). Thus, UVRAG supports genetic and genomic stability. Notably, neither of these phenotypes is the result of autophagic defects associated with UVRAG downregulation ([@bib134], [@bib142]), even though *bona fide* autophagic responses are known to contribute to the maintenance of genomic homeostasis ([@bib48], [@bib72]). Indeed, *Atg5* ^*−/−*^ MEFs are equally sensitive to UVRAG depletion with regards to DNA damage and centrosome dysfunction as their wild-type counterparts ([@bib134], [@bib142]). Rather, the genoprotective effects of UVRAG reflect its ability to support non-homologous end-joining (a form of DNA repair specific for DSBs) by binding to the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex, to promote the repair of UV-driven DNA photolesions following interaction with damage-specific DNA binding protein 1 (DDB1), and to regulate centrosome functions upon binding to centrosomal protein 63 (CEP63) ([@bib134], [@bib142]). All these activities are molecularly and functionally independent of the capacity of UVRAG to bind BECN1 and hence stimulate autophagy ([@bib134], [@bib142]). In line with this notion, *UVRAG* is often affected by monoallelic mutations in colorectal and gastric carcinomas with high degrees of genomic instability (so-called microsatellite instable), but these mutations fail to affect autophagic responses ([@bib54]). Similarly, a truncated variant of UVRAG expressed by some CRCs has been associated with an autophagy-independent DNA repair defect and consequent increased sensitivity to genotoxic chemotherapy ([@bib37]). BECN1 appears to share with UVRAG the ability to regulate centrosome functions in an ATG5-independent manner, especially in the context of DNA damage ([@bib85]). Whether the physical interaction between UVRAG and BECN1 is required for centrosome regulation by UVRAG remains to be elucidated.

*Uvrag* ^*−/−*^ T cells also display defects in homeostatic proliferation that cannot be related to the autophagic functions of UVRAG and cannot be explained by the alterations imposed by the absence of *Atg5* or *Atg7* (encoding another core component, the autophagy machinery) ([@bib1]). Thus, *Uvrag* ablation compromises CD8^+^ T cell responses to lymphocytic choriomeningitis virus (LMCV) in the absence of major alterations in autophagic flux ([@bib1]). The deletion of *Atg5* or *Atg7* similarly impairs the survival of effector CD8^+^ T cells and their ability to establish immunological memory upon challenge ([@bib90], [@bib132]). Moreover, the conditional deletion of *Atg3*, *Atg5*, or *Atg7* from the CD4^+^ cellular compartment, which encompasses CD4^+^ T cells as well as multiple populations of innate lymphoid cells (ILCs), or from the NKp46^+^ compartment, corresponding to ILCs only, imposes a major defect in homeostatic proliferation to multiple ILC populations ([@bib83], [@bib88]). Importantly, although the defects imposed on T lymphocytes and ILCs by the deletion of *Atg3*, *Atg5*, or *Atg7* are generally attributed to compromised autophagic responses ([@bib11]), no strict experimental evidence in support of this interpretation is currently available. Thus, it is tempting to speculate that ATG3, ATG5, and ATG7 resemble UVRAG in its ability to support T cell homeostasis irrespective of *bona fide* autophagic responses.

Pathogen Invasion {#sec1.7}
-----------------

A variety of viruses, including several members of the *enterovirus* genus, have evolved strategies to hijack the molecular machinery for autophagy, which often mediates antiviral effects by promoting the lysosomal degradation of cytosolic virions or components thereof, ([@bib9]) to their own benefit. Such strategies go beyond the simple inhibition of autophagic flux, which would suppress the autophagic disposal of cytosolic virions but at the same time would render host cells considerably more sensitive to undergo premature apoptotic cell death and potentially compromise viral replication ([@bib23], [@bib64], [@bib115]). Rather, they involve the modulation of various components of the autophagic apparatus resulting in (1) increased availability of autophagosomes or other membranes that support viral replication via LC3 ([@bib3], [@bib129]); (2) diversion of the autophagic flux from lysosomal degradation, as a consequence of compromised interaction between synaptosome associated protein 29 (SNP29) and pleckstrin homology and RUN domain containing M1 (PLEKHM1), which normally underlies autophagosome-to-lysosome fusion ([@bib76], [@bib122]); (3) early release of virus-loaded exosome-like microvesicles that bear autophagosomal markers ([@bib97], [@bib109]); and (4) ultimately, activation of apoptotic cell death for massive viral dissemination ([@bib130]).

The modulation of LC3 or other components of the autophagy machinery as a means to hijack intracellular membranes for viral replication in an autophagy-independent manner is an extraordinarily common mechanism (as an estimate, 36% of the autophagy-related cellular proteome influence the replication of one or multiple viruses irrespective of autophagic degradation) ([@bib73]) shared by multiple RNA viruses other than enteroviruses, including the equine arteritis virus (EAV) ([@bib77]), the hepatitis C virus ([@bib108]), and coronaviruses ([@bib95]). Similarly, LC3 appears to support the intracellular propagation of the bacterial parasite *Chlamydia trachomatis*, by a mechanism that can be fully segregated from increased autophagic flux, which is detrimental to the pathogen ([@bib2]). Many DNA viruses, including members of the *adenoviridae* and *herpesviridae* families, have also evolved strategies to control various components of the autophagy machinery to their own benefit. In this case, however, modulation seems focused on actual autophagic flux rather than on autophagy-independent signaling pathways ([@bib98], [@bib137]). We surmise that this discrepancy is only apparent, potentially originating from the autophagy-biased approach with which the phenotypes linked to genetic or pharmacological inhibition of single components of the autophagy machinery have been interpreted so far.

The obligate intracellular bacterium *Legionella pneumophila* encodes RavZ, a protease that, upon secretion to the cytosol of infected cells, specifically hydrolyzes the amide bond between the C-terminal glycine and the adjacent aromatic residue of all mammalian MAP1LC3 family members ([@bib10]). Such a cleavage irreversibly prevents the (re-)lipidation of MAP1LC3 proteins, hence inhibiting autophagy ([@bib10]). However, given that *L. pneumophila* lives within a replicative organelle derived from the phagosome, it is unclear why inhibition of autophagy, per se, would be beneficial to the pathogen. As an alternative, RavZ may operate to prevent LAP, thus inhibiting the fusion of the replicative organelle with lysosomes and consequent pathogen eradication. As soil amoeba are the primary host of *Legionella spp.* ([@bib96]), it is tempting to speculate that LAP is a major non-canonical function for autophagy regulators in such hosts.

Conclusions {#sec1.8}
-----------

Most, if not all, components of the molecular apparatus for autophagy mediate non-autophagic functions ([Figure 3](#fig3){ref-type="fig"} ). Although at this point in time some proteins involved in autophagy have not yet been attributed non-autophagic roles (e.g., ATG2), we surmise that this only reflects our limited knowledge of their biology and that all components of the autophagy proteome *de facto* serve multiple functions. Precisely characterizing the autophagy-independent functions of the autophagy machinery and their pathophysiological relevance calls for the design of refined experimental strategies that fully uncouple autophagic versus non-autophagic activities, such as the generation of mice genetically engineered to express a variant of FIP200 that cannot bind ATG13 ([@bib8]). This approach relies on in-depth structure-to-function relationship data that are not available for all autophagy-relevant proteins and their interactors. Indeed, considerable attention has been given so far to the structural characterization of single proteins and protein complexes linked to degradative autophagy, including ATG3 ([@bib133]), ATG4B ([@bib119]), BECN1 ([@bib61]), VPS34 ([@bib75], [@bib100]), the ATG12-ATG5:ATG16L1 complex ([@bib82]), LC3B ([@bib118]), and several others. Although these studies provided profound mechanistic insights into *bona fide* autophagic responses ([@bib61], [@bib105]) and fostered the development of targeted inhibitors ([@bib75], [@bib91]), experimental design was often, if not always, biased toward autophagy-relevant domains and interactions. That said, it may not always be feasible to molecularly dissociate the autophagic and non-autophagic functions of a specific protein, even in the presence of detailed data on structure and physical interactions.Figure 3Non-autophagic Functions of the Autophagy ApparatusA large number of autophagy-relevant proteins mediate non-autophagic effects related to membrane biology and other cellular functions. Interestingly, many of these proteins operate in early steps of *bona fide* autophagic responses (e.g., initiation, nucleation, and elongation).ER, endoplasmic reticulum; GA, Golgi apparatus; LAP, LC3-associated phagocytosis; PRR, pattern recognition receptor.

An additional layer of complexity originates from the fact that several proteins that participate in multiple cellular functions exist in limiting amounts, implying that the inhibition of one pathway may result in the hyperactivation of another one. For instance, displacement of UVRAG from RINT1, which inhibits retrograde GA-to-ER vesicular trafficking, results in the activation of autophagy as a consequence of increased UVRAG availability for binding to BECN1 ([@bib36]). Moreover, it is likely that the molecular links between degradative autophagy and non-autophagic cellular functions may exhibit considerable degrees of context dependence (i.e., they may vary considerably depending on cell type, differentiation stage, etc.). An intriguing possibility is that cells may actively route disposable cytosolic material to autophagic degradation versus non-canonical secretion as a means to control the emission of damage signals into the microenvironment ([@bib26], [@bib136]). Although preclinical data in support of this notion is emerging, additional work is required to clarify the mutual regulation of autophagy and non-autophagic pathways and its pathophysiological implications.

Finally, autophagy is a redundant process that can occur via a plethora of mechanisms, including several variants of macroautophagy that do not rely on canonical regulators (e.g., they occur irrespective of ATG5 or ATG7) ([@bib42], [@bib66], [@bib81]) as well as microautophagy and CMA ([@bib24]). Thus, other variants of autophagy can compensate for the lack of macroautophagy in the degradation of some substrates, such as ferritin ([@bib31], [@bib68]). Importantly, the molecular machinery involved in the degradation of ferritin in this scenario involves regulators of macroautophagy including ATG9, FIP200, and VPS34 ([@bib31], [@bib68]). Thus, pharmacological inhibitors or genetic interventions specific for any of these proteins cannot be used to identify the precise mechanism underlying the autophagic degradation of ferritin.

Of note, components of the autophagy machinery appear to mediate non-autophagic functions mostly, although not exclusively, in the context of (1) vesicle uptake, trafficking, release, and other processes involving membrane rearrangements (e.g., cytokinesis); and (2) mechanisms for the innate and adaptive control of invading pathogens (including the regulated death of infected cells) ([Table 2](#tbl2){ref-type="table"}). Thus, membrane trafficking (in the extended sense of the term) and pathogen control constitute the most ancient evolutionary hubs for autophagy to interact with non-autophagic functions. In line with this notion, autophagy-independent effects for the orthologs of mammalian ULK1, UVRAG, BECN1, ATG9, and ATG16L1 in endocytosis, phagocytosis, and secretion have been documented in lower eukaryotes ([@bib39], [@bib56], [@bib62], [@bib107], [@bib124], [@bib131]). Moreover, the majority of autophagy-related proteins with non-autophagic functions operate at early phases of degradative autophagy (i.e., initiation, nucleation, and elongation) ([Table 1](#tbl1){ref-type="table"}). Taken together, these observations may suggest that an ancient molecular machinery regulating basic membrane functions (e.g., phospholipid insertion, curvature regulation) in lower eukaryotes may have diversified to control broad cellular processes (e.g., phagocytosis, vesicular trafficking, autophagy) while retaining shared molecular components.

In summary, autophagy stands out as a key process for the lysosomal degradation of cytosolic entities that is highly interconnected with several other biological functions. Such a connection does not only reflect the key role of *bona fide* autophagic responses in the maintenance of metabolic homeostasis but also the ability of multiple autophagy-relevant proteins to mediate non-autophagic functions. We surmise that elucidating such molecular crosstalk in detail will provide important insights into the pathophysiology of multiple disorders and potentially foster the identification of actionable therapeutic targets.
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[^1]: ADCD, autophagy-dependent cell death; ER, endoplasmic reticulum; GA, Golgi apparatus; LAP, LC3-associated phagocytosis; PRR, pattern recognition receptor.

[^2]: Referring to bacteria replicating in the cytoplasm of infected cells

[^3]: ADCD, autophagy-dependent cell death; ER, endoplasmic reticulum; GA, Golgi apparatus; LAP, LC3-associated phagocytosis; PRR, pattern recognition receptor.

[^4]: Partially unrelated to membrane biology

[^5]: Referring to the replication of pathogens in the cytoplasm of infected cells

[^6]: CFLAR, CASP8 and FADD-like apoptosis regulator; CST, cystatin; TNFR1 (official name, TNFRSF1A), TNF receptor superfamily member 1A.
